Sibylla Biotech Appoints Usman Azam CEO, Gianluca Fuggetta CFO, and Expands Executive Team to Drive Transition to ClinicGlobeNewsWire • 10/13/26
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months AdministrationGlobeNewsWire • 10/01/26
Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement DisordersGlobeNewsWire • 09/29/26
Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities ConferenceGlobeNewsWire • 09/17/26
Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire • 08/25/26
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateGlobeNewsWire • 07/16/26
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's DiseaseGlobeNewsWire • 06/29/26
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert SummitGlobeNewsWire • 06/10/26
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026GlobeNewsWire • 05/26/26
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate UpdateGlobeNewsWire • 05/11/26
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026GlobeNewsWire • 04/24/26
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate UpdateGlobeNewsWire • 03/26/26
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026GlobeNewsWire • 03/18/26
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory UpdateGlobeNewsWire • 03/12/26
Gain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/19/26
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference WeekGlobeNewsWire • 01/07/26
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287GlobeNewsWire • 01/06/26
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's DiseaseGlobeNewsWire • 12/18/25
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's DiseaseGlobeNewsWire • 12/18/25
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to BuyZacks Investment Research • 12/08/25
Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/17/25